European Commission approves Orfadin® oral suspension

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.

 "The European Medicines Agency has called for more child-friendly formulations and the new oral suspension formulation is a demonstration of Sobi's commitment to the needs of the infants and children diagnosed with HT-1 early in life," says Birgitte Volck, Chief Medical Officer of Sobi. "An oral suspension of Orfadin for paediatric use will facilitate accurate dosing for infants and small children, and contribute to improving quality of life for patients and caregivers."

The oral suspension will be made available to patients throughout Europe in H2 2015.

Before pharmacological treatment was available, fewer than one third of infants diagnosed with HT-1 before two months of age lived past their second birthday.^[1] Treatment with Orfadin combined with dietary restriction of tyrosine and phenylalanine and more widespread new-born screening, leading to early diagnosis have dramatically improved outcomes for HT-1 patients.[2]

Orfadin capsules are approved in the EU and several other countries for the treatment of patients with confirmed diagnosis of HT-1 in combination with dietary restriction of tyrosine and phenylalanine.

---

About Orfadin
Orfadin (nitisinone) blocks the breakdown of tyrosine, thereby reducing the amount of toxic by-products in the body. People with Hereditary Tyrosinaemia type-1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic by-products are formed and accumulate in the body, which can cause liver failure, renal dysfunction and neurological complications. In the most common form of the disease, symptoms arise within the first six months of the child's life. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine remains in the body. Approximately 1,000 persons are identified as living with HT-1 today.

Orfadin is a proprietary product and is developed by and marketed globally by Sobi.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on Nasdaq OMX Stockholm. More information is available at www.sobi.com.

For more information please contact